Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen
- Sponsor
- Anders Kvanta
- Study ID
- NCT02274259
- Phase
- PHASE4
- Status
- Completed
Conditions
- Central Retinal Vein Occlusion
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Aflibercept — DRUGAflibercept injection is given at every visit. Time to next treatment according to presence of macular edema
- Ranibizumab — DRUGRanibizumab injection is given at every visit. Time to next treatment according to presence of macular edema
Study Details
Comparing ranibizumab and aflibercept in a treat and extend algorithm evaluating the number of needed injections over a 18 month period in patients with newly diagnosed CRVO.
Key Dates
- Start date
- Oct 31, 2014
- Status verified
- Dec 2020
- Primary completion
- Jun 30, 2015
- Completion
- Dec 31, 2016
Study Design
- Enrollment
- 40 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: AfliberceptAflibercept injection is given at every visit. Time to next treatment according to presence of macular edema
- Active Comparator: RanibizumabRanibizumab injection is given at every visit. Time to next treatment according to presence of macular edema
Primary Outcome Measure
The number of needed injections over a 18 month period comparing ranibizumab and aflibercept. [ Time Frame: 18 months ]